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Reports of human infections with environmental fungi are on the increase throughout the world. Many of 
these reports describe infections caused by new agents, as 
well as by traditional agents with new virulence factors or 
new mechanisms of infection. Fungal infections historical-
ly have been underrecognized and difficult to detect, and 
treatment options are poor.
The reasons for their emergence are likely multifac-
torial. The advent of medical progress–including the wide 
use of medical hardware, such as central lines; success-
ful management of immunosuppression in patients with 
transplanted organs; and immunomodulatory agents for 
treating underlying diseases from cancer to rheumatoid 
arthritis–has contributed to the increase in fungal infec-
tions in immunocompromised hosts. Risk factors such 
as changes in land use, seasonal migration, international 
travel, extreme weather, and natural disasters, and the use 
of azole antifungal agents in large-scale agriculture are 
believed to underlie many of the increases in community-
acquired fungal infections.
Because fungal infections are frequently underrecog-
nized and difficult to detect, one of the largest gaps in our 
understanding of their epidemiology is determining the 
incidence of disease. In an article in this issue of Emerg-
ing Infectious Diseases, Sondermeyer et al. document the 
incidence and cost of hospitalizations in California caused 
by Valley fever (coccidioidomycosis), a fungal infection 
endemic to the southwestern United States and parts of 
Latin America (1). This article reports that during 2000–
2011, there were >25,000 Valley fever–associated hospi-
talizations in California and >$2 billion in hospital costs. 
The rate of hospitalizations increased over the study pe-
riod from 2.3 to 5.0 cases/100,000 population, a finding 
that supports other recent publications documenting the 
increasing incidence of Valley fever in the United States 
(2,3). Although the reasons for this increase are not well 
understood, the practical effect of this increasing incidence 
has been seen in many settings, including the California 
state prison system. Recently, a federal court ordered the 
prison system to move prisoners believed to be at high risk 
for Valley fever (including Blacks, persons >55 years of 
age, and persons with preexisting diabetes) out of 2 prisons 
in the San Joaquin Valley, which is the region in California 
to which coccidioidomycosis is endemic.
Fungal diseases also appear to be emerging beyond 
their traditionally described borders for reasons that are 
not entirely understood. One article in this issue reports the 
incidence of Cryptococcus gattii disease, once believed to 
be restricted to tropical regions, but which is now found 
in locations as disparate as Vancouver Island, Canada and 
parts of the southeastern United States (4). Although this 
organism is genetically related to C. neoformans, a cause of 
meningitis in HIV-infected persons, C. gattii is frequently 
associated with a different spectrum of disease, prominent-
ly pneumonia. In another article in this issue, Nucci et al. 
report an increase in incidence of community-associated 
Fusarium spp. infections in a cancer ward in Brazil (5). In 
this study, Fusarium spp. caused an increase in invasive 
infections, which usually started as skin or nail infections, 
in immunocompetent and immunosuppressed patients. 
Although the root cause was not determined, speculation 
has centered on changes in land use patterns and agricul-
tural practices in Brazil. Also in this issue, a novel agent 
of fungemia, Candida auris, is reported as having been 
detected in India (6). All isolates reported in this article 
were resistant to the antifungal agent fluconazole, which 
is concerning because fluconazole is frequently the first-
line treatment for invasive Candida spp. infections in many 
countries. Finally, an article by Fong et al. provides sero-
logic evidence that Pneumocystis jirovecii may be trans-
mitted between patients and providers in the health care 
setting, a finding that could affect future infection control 
policies (7).
Because most invasive fungal infections have high 
mortality rates, reducing the incidence of these diseases 
often relies on rapid and specific diagnostics, effective an-
tifungal drugs, novel immunotherapeutic strategies, and 
adherence to infection control and sterility practices. Re-
cently, we have seen examples of successes and failures 
in this area. In regions with high HIV prevalence, use of 
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novel lateral-flow diagnostic tests for cryptococcal disease 
has opened the door to systematic screening and point-of-
care testing in asymptomatic persons with low CD4 cell 
counts and may result in reduction of deaths caused by this 
disease (8,9). Conversely, recent contamination of a widely 
distributed injectable steroid medication with fungal organ-
isms, particularly the black mold Exserohilum rostratum, 
caused the largest health care–associated outbreak in the 
United States; as of July 1, 2013, there have been 749 cases 
of meningitis and related infections among persons in 20 
states and 61 deaths (10,11). Swift public health actions, 
including notification of patients and providers, led to rapid 
clinical assessments and institution of antifungal therapy 
among infected persons, thereby reducing the mortality 
rate and effects of this disease (12).
Broader control of fungal exposures in the community 
can also be improved by awareness, especially education 
regarding high-risk practices and activities. Outbreaks of 
histoplasmosis linked to construction and cleaning activi-
ties in places contaminated with bird or bat guano have 
led to production of educational materials describing how 
risk can be mitigated (13). Furthermore, recent advances 
in whole-genome sequencing are being explored to sug-
gest novel vaccine and diagnostic targets for the agent of 
Valley fever (14).
Fungal infections remain serious and underappreci-
ated causes of illness and death. Much can be done to pre-
vent the consequences of these infections, although envi-
ronmental exposure to these agents may not be entirely 
avoidable in the community. Continued public health 
efforts toward defining, characterizing, and tracking the 
emergence of fungal infections can help to focus studies 
on priority infections and settings. Future translational re-
search is urgently needed to develop novel diagnostics, 
vaccines, and treatments as more is learned about the 
pathogenesis of fungal infections and the biology of fun-
gal agents.
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